BioSpace News Archive

Gene Editing

Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline

In an effort to expand its cash runway beyond 12 months, Prime Medicine has signed a deal with Bristol Myers Squibb worth a potential $3.5 billion, while also streamlining its pipeline to trim costs.

September 30, 2024

·

2 min read

·

Annalee Armstrong

Johnson & Johnson's business center in Switzerland

Drug Development

J&J Posts Positive Phase III Results for Carvykti and Darzalex Faspro in Multiple Myeloma Trials

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual disease-negativity, boosting the prospects of two key growth drivers for the company.

September 30, 2024

·

2 min read

·

Nick Paul Taylor

M&A

Roche Doubles Down on Breast Cancer With $850M for Regor’s CDK Inhibitors

The acquisition was featured Monday in Roche’s Pharma Day presentation, which also included projections of more than $3 billion in annual sales from three early-stage obesity and diabetes drugs.

September 30, 2024

·

2 min read

·

Heather McKenzie

A scientist with pill bottles in front of FDA headquarters

Regulatory

FDA Action Alert: Biofrontera, BMS and Zealand

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.

September 30, 2024

·

4 min read

·

Tristan Manalac

Pictured: MRI images of the brain for neurological

Drug Development

Novartis’ Lutathera Radiopharma Therapy Improves Survival in Difficult-to-Treat Brain Tumors

Six months after treatment with the radiopharmaceutical therapy, 77.8% of patients with meningioma were alive and had not experienced further disease progression, beating the 26% benchmark established in earlier studies.

September 30, 2024

·

2 min read

·

Nick Paul Taylor

Press Releases

Resilience Appoints Dr. Susan Billings, Chief Commercial Officer

September 30, 2024

·

3 min read

Press Releases

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema